
Prelude Therapeutics Incorporated: shareholders and insiders
Price
$3.23
November 20, 2026Market cap $333M
What Ploutos Investor adds for Prelude Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 2 fiscal years, from 2024
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 22, 2025 to Jun 10, 2026, from their own Form 4 filings.
Bought on the market
$12M
1 person
Sold on the market
–
nobody
From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
No sales in the period.
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 22, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $12M by 1 person·no sales
- 2025: no buys, no sales
- 2026: bought $12M by 1 person, no sales
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 10, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by PRLD's officers and directors from 2020 up to November 21, 2025, 6 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 1 more, back to 2020
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Orbimed Advisorswith 3 more personsShare of class16.0%
- Baker Bros. Advisors LPwith 3 more personsShare of class15.5%
- Vaddi KrishnaShare of class13.2%
- IncyteShare of class9.90%
- RA Capital Management, L.P.with 3 more personsShare of class9.90%
- Soleus Private Equity Fund III, L.P.with 8 more personsShare of class5.20%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Orbimed Advisorswith 3 more persons | 16.0% | 12.94M | Apr 23, 2026 | 13D/A | |
| Baker Bros. Advisors LPwith 3 more persons | 15.5% | 10.30M | Apr 22, 20262 filings since Jun 13, 2025 | 13D/A | |
| Vaddi Krishna | 13.2% | 6.75M | Feb 13, 20263 filings since Feb 14, 2025 | 13G/A | |
| Incyte | 9.90% | 4.37M | Nov 7, 2025 | 13G | |
| RA Capital Management, L.P.with 3 more persons | 9.90% | 6.48M | Apr 28, 2026 | 13G | |
| Soleus Private Equity Fund III, L.P.with 8 more persons | 5.20% | 3.38M | Jul 8, 2026 | 13G |
What the holders on a 13D state as their purpose
From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.
Orbimed Advisors16.0%From the filing of Apr 23, 2026
The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the…
From the filing of Apr 23, 2026Baker Bros. Advisors LP15.5%From the filing of Apr 22, 2026
Item 4 of Schedule 13D is supplemented and amended, as the case may be, as follows: The disclosure in Item 6 below is incorporated herein by reference. On April 20, 2026, Prelude Therapeutics Incorporated (the "Issuer") entered into an underwriting agreement (the "Underwriting Agreement") with Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Citizens JMP Securities LLC (the "Underwriters"), related to a public offering (the "Offering") of 18,018,014 shares of common stock of the Issuer ("Common Stock"), at a price to the public of $4.44 per share and in lieu of Common Stock to investors who so chose, prefunded warrants to purchase up to 2,252,252 shares of the Issuer's Common Stock (the…
From the filing of Apr 22, 2026
Fell to 5% or less (1)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
- Deerfield Mgmt, L.P.0.00%Feb 13, 202513G/A
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Citadel Advisors (Griffin)In the quarter+844%
- Millennium Mgmt (Englander)In the quarter-45%
- D.E. ShawIn the quarter
- Renaissance TechnologiesIn the quarter+5.9%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Citadel Advisors (Griffin) | 212.9K | +844% | $800.0K | 0.00% |
| Millennium Mgmt (Englander) | 466.8K | -45% | $1.8M | 0.00% |
| D.E. Shaw | 24.4K | $100.0K | 0.00% | |
| Renaissance Technologies | 297.7K | +5.9% | $1.2M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 4.94% of its shares outstanding were held short, +11.4% since the report before.
- Shares held short
- 5.10M
- 4.94%
- Since the report before4.58M on Sep 30, 2026
- +11.4%
- 11.5
- 444.2K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 94%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 799.9K
- Nov 15, 2023: Shares held short 804.4K
- Nov 30, 2023: Shares held short 741.0K
- Dec 15, 2023: Shares held short 680.1K
- Dec 29, 2023: Shares held short 446.9K
- Jan 12, 2024: Shares held short 451.5K
- Jan 31, 2024: Shares held short 522.0K
- Feb 15, 2024: Shares held short 503.8K
- Feb 29, 2024: Shares held short 619.1K
- Mar 15, 2024: Shares held short 643.2K
- Mar 28, 2024: Shares held short 621.9K
- Apr 15, 2024: Shares held short 604.0K
- Apr 30, 2024: Shares held short 630.6K
- May 15, 2024: Shares held short 608.9K
- May 31, 2024: Shares held short 585.1K
- Jun 14, 2024: Shares held short 566.9K
- Jun 28, 2024: Shares held short 559.8K
- Jul 15, 2024: Shares held short 528.3K
- Jul 31, 2024: Shares held short 771.3K
- Aug 15, 2024: Shares held short 1.43M
- Aug 30, 2024: Shares held short 2.43M
- Sep 13, 2024: Shares held short 3.33M
- Sep 30, 2024: Shares held short 2.49M
- Oct 15, 2024: Shares held short 2.49M
- Oct 31, 2024: Shares held short 2.94M
- Nov 15, 2024: Shares held short 2.90M
- Nov 29, 2024: Shares held short 3.06M
- Dec 13, 2024: Shares held short 3.26M
- Dec 31, 2024: Shares held short 3.38M
- Jan 15, 2025: Shares held short 3.12M
- Jan 31, 2025: Shares held short 3.15M
- Feb 14, 2025: Shares held short 3.10M
- Feb 28, 2025: Shares held short 2.16M
- Mar 14, 2025: Shares held short 2.25M
- Mar 31, 2025: Shares held short 2.38M
- Apr 15, 2025: Shares held short 2.26M
- Apr 30, 2025: Shares held short 978.6K
- May 15, 2025: Shares held short 877.7K
- May 30, 2025: Shares held short 945.7K
- Jun 13, 2025: Shares held short 841.0K
- Jun 30, 2025: Shares held short 545.7K
- Jul 15, 2025: Shares held short 520.8K
- Jul 31, 2025: Shares held short 594.6K
- Aug 15, 2025: Shares held short 510.2K
- Aug 29, 2025: Shares held short 531.2K
- Sep 15, 2025: Shares held short 538.4K
- Sep 30, 2025: Shares held short 601.1K
- Oct 15, 2025: Shares held short 515.1K
- Oct 31, 2025: Shares held short 567.1K
- Nov 14, 2025: Shares held short 1.28M
- Nov 28, 2025: Shares held short 995.8K
- Dec 15, 2025: Shares held short 1.28M
- Dec 31, 2025: Shares held short 1.47M
- Jan 15, 2026: Shares held short 1.68M
- Jan 30, 2026: Shares held short 2.07M
- Feb 13, 2026: Shares held short 2.38M
- Feb 27, 2026: Shares held short 2.27M
- Mar 13, 2026: Shares held short 2.28M
- Mar 31, 2026: Shares held short 2.32M
- Apr 15, 2026: Shares held short 1.81M
- Apr 30, 2026: Shares held short 1.55M
- May 15, 2026: Shares held short 1.85M
- May 29, 2026: Shares held short 1.69M
- Jun 15, 2026: Shares held short 1.79M
- Jun 30, 2026: Shares held short 2.82M
- Jul 15, 2026: Shares held short 3.29M
- Jul 31, 2026: Shares held short 3.67M
- Aug 14, 2026: Shares held short 3.82M
- Aug 31, 2026: Shares held short 3.59M
- Sep 15, 2026: Shares held short 3.63M
- Sep 30, 2026: Shares held short 4.58M
- Oct 15, 2026: Shares held short 5.10M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading66.4% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 66.4% of the shares in the reported trades were short sales, against 39.8% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 66.4%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 39.8%
- Change
- +26.6 pts
- Short sales a dayon average, of 82.9K shares
- 55.1K
- More than atof 3,666 US-listed companies, same days
- 94%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 43.2%
- Oct 15, 2026: Short sales 34.8%
- Oct 16, 2026: Short sales 51.2%
- Oct 19, 2026: Short sales 43%
- Oct 20, 2026: Short sales 30.5%
- Oct 21, 2026: Short sales 24.2%
- Oct 22, 2026: Short sales 25.5%
- Oct 23, 2026: Short sales 29%
- Oct 26, 2026: Short sales 66.8%
- Oct 27, 2026: Short sales 47.9%
- Oct 28, 2026: Short sales 48.4%
- Oct 29, 2026: Short sales 62.4%
- Oct 30, 2026: Short sales 56.5%
- Nov 2, 2026: Short sales 77%
- Nov 3, 2026: Short sales 64.2%
- Nov 4, 2026: Short sales 73%
- Nov 5, 2026: Short sales 60.7%
- Nov 6, 2026: Short sales 80.5%
- Nov 9, 2026: Short sales 67.8%
- Nov 10, 2026: Short sales 76.9%
- Nov 11, 2026: Short sales 81.2%
- Nov 12, 2026: Short sales 87%
- Nov 13, 2026: Short sales 54.7%
- Nov 16, 2026: Short sales 49.1%
- Nov 17, 2026: Short sales 43.8%
- Nov 18, 2026: Short sales 61.2%
- Nov 19, 2026: Short sales 71%
- Nov 20, 2026: Short sales 60.5%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Krishna VaddiCEODirectly2.00M
- OrbiMed Genesis GP LLCDirector,TenPercentOwnerDirectly–
- David P BonitaDirector,TenPercentOwnerDirectly–
- Andrew CombsChief Chemistry OfficerDirectly480.1K
- Bryant David LimCLO, Interim CFO, Corp Sec.Directly27.4K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Krishna VaddiCEO | 2.00M | 142.6K | Mar 25, 2025 | Form 4 |
| OrbiMed Genesis GP LLCDirector,TenPercentOwner | – | 1.13M | Apr 21, 2026 | Form 4 |
| David P BonitaDirector,TenPercentOwner | – | 1.13M | Apr 21, 2026 | Form 4 |
| Andrew CombsChief Chemistry Officer | 480.1K | – | Mar 25, 2025 | Form 4 |
| Bryant David LimCLO, Interim CFO, Corp Sec. | 27.4K | – | Dec 19, 2024 | Form 4 |
A lower bound: it counts only the 5 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IWCiShares Micro-Cap ETFWeight in the fund0.03%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.01%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.01%
- IWMiShares Russell 2000 ETFWeight in the fund0.00%
- VXFVanguard Extended Market Index FundWeight in the fund0.00%
- VTIVanguard Total Stock Market Index FundWeight in the fund0.00%
- DFASDimensional U.S. Small Cap ETFWeight in the fund0.00%
7 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 47
- Q4 2025: Managers 48
- Q1 2026: Managers 56
- Q2 2026: Managers 75
Institutional investors by quarter
The fund managers holding PRLD, quarter by quarter, from Q3 2020 to Q2 2025, 20 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 75 managers held 49.60M shares, worth $264M. During the quarter 33 opened a position, 15 closed one, 23 added and 8 trimmed.
The largest holders, Q2 2026
- Orbimed AdvisorsIn the quarter+26%
- Baker Bros. AdvisorsIn the quarter
- Ra Capital ManagementIn the quarter
- Soleus Capital ManagementIn the quarter
- Kynam Capital ManagementIn the quarter+52%
- Vanguard Capital ManagementIn the quarter+63%
- BlackRockIn the quarter+458%
- Sphera Funds ManagementIn the quarter+83%
- Two Sigma InvestmentsIn the quarter+7.6%
- ADAR1 Capital ManagementIn the quarter+489%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Orbimed Advisors | 13.72M | +26% | $73M |
| Baker Bros. Advisors | 10.12M | $54M | |
| Ra Capital Management | 6.48M | $35M | |
| Soleus Capital Management | 3.38M | $18M | |
| Kynam Capital Management | 2.42M | +52% | $13M |
| Vanguard Capital Management | 2.01M | +63% | $11M |
| BlackRock | 1.80M | +458% | $9.6M |
| Sphera Funds Management | 1.02M | +83% | $5.4M |
| Two Sigma Investments | 993.4K | +7.6% | $5.3M |
| ADAR1 Capital Management | 900.9K | +489% | $4.8M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Prelude Therapeutics's filings show?
Who buys and sells is one part of Prelude Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have PRLD's insiders bought or sold?
From Jun 10, 2026 to Jun 10, 2026 Prelude Therapeutics's insiders reported no purchase or sale of shares on the market.
Which well-known managers hold PRLD?
4 of the managers we track held the shares on Sep 30, 2026. The largest position was Millennium Mgmt (Englander)'s, worth $1.8M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.